Påhlman S, Esscher T, Bergh J, Steinholtz L, Nöu E, Nilsson K
Tumour Biol. 1984;5(2):119-26.
The use of neuron-specific enolase (NSE, E.C. 4.2.1.11) as a clinical marker for neuroblastoma and small-cell carcinoma of lung (SCCL) is presented. Both tumors have a high content of NSE as demonstrated enzymatically or by immunocytochemistry. Other retroperitoneal tumors in children and other lung tumors had insignificant NSE concentrations. NSE can thus be used in the differential diagnosis of neuroblastoma and SCCL. 73% of patients with SCCL had elevated serum NSE levels. The corresponding figure for patients with other types of lung cancer was 3%. There was a good correlation between serum NSE levels and the clinical course of patients with SCCL.
本文介绍了神经元特异性烯醇化酶（NSE，E.C. 4.2.1.11）作为神经母细胞瘤和肺小细胞癌（SCCL）临床标志物的应用。通过酶法或免疫细胞化学方法均证实，这两种肿瘤中NSE含量都很高。儿童的其他腹膜后肿瘤以及其他肺部肿瘤中NSE浓度则无显著意义。因此，NSE可用于神经母细胞瘤和SCCL的鉴别诊断。73%的SCCL患者血清NSE水平升高。其他类型肺癌患者的相应比例为3%。SCCL患者血清NSE水平与临床病程之间存在良好的相关性。
